A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Status unconfirmed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Secondary Progress Multiple Sclerosis, Multiple Sclerosis

In brief

Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo. 200 subjects with Secondary Progressive SPMS

Key facts

Study ID

NCT02057159

Run by

Immune Response BioPharma, Inc.

People needed

200

Starts

2020-03-09

Expected to finish

2023-03-09

Last updated by the study team

2020-03-11

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is between 18 and 50 years of age, inclusive.
• Definite MS by the revised McDonald criteria (2005) (Appendix A), with a Secondary Progressive course.
• Expanded Disability Status Scale (EDSS) >=score 3.5 (Appendix B).
• Two or more documented clinical relapses of MS in the preceding 24 months OR one documented clinical relapse of MS in the preceding 1 2 months prior to screening .
• Laboratory values within the following limits:
• Creatinine 1 . 5 x high normal.
• Hemoglobin

Where it is running

• CRO — San Diego, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.